Literature DB >> 7528730

Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).

K Hatano1, J B Goldberg, G B Pier.   

Abstract

Virulent strains of Pseudomonas aeruginosa are either of a nonmucoid, lipopolysaccharide (LPS)-smooth or mucoid, LPS-rough phenotype, and immunity to these different variants is efficiently mediated by antibodies specific to O antigens or mucoid exopolysaccharide (also called alginate), respectively. In addition to O side chains and core polysaccharide components, the LPS of P. aeruginosa also contains neutral-polysaccharide components that express antigenic determinants common to many clinical isolates. We evaluated antibodies specific to neutral polysaccharides for the ability to mediate opsonic killing and protective immunity. Antibodies to these antigens mediated opsonic killing of poorly virulent nonmucoid LPS-rough isolates but not of isogenic strains with either a LPS-smooth or a mucoid phenotype. Antibodies to neutral-polysaccharide antigens also failed to protect neutropenic mice from challenge with modest doses of LPS-smooth P. aeruginosa strains (< 10(3) CFU per mouse), whereas O-antigen-specific antibodies were highly protective. Antibodies to neutral polysaccharides deposited significantly (P = 0.002) more C3 onto LPS-rough strains than did antibodies to O side chains, but this situation was reversed when isogenic LPS-smooth strains were tested. Given that protective immunity against P. aeruginosa must be directed against either nonmucoid LPS-smooth strains or mucoid LPS-rough strains, it appears that antibodies specific to neutral-polysaccharide antigens do not protect against P. aeruginosa infection. Lack of protection is likely due to the ability of both O side chains and mucoid exopolysaccharide (alginate) to interfere with the opsonic killing activity of neutral-polysaccharide-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7528730      PMCID: PMC172952          DOI: 10.1128/iai.63.1.21-26.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  In vitro and in vivo functional activities of monoclonal antibodies reactive with Pseudomonas aeruginosa serogroup 6 lipopolysaccharides.

Authors:  M Pollack; M Tao; M Akiyama; G B Pier; N L Koles
Journal:  Antibiot Chemother (1971)       Date:  1991

Review 2.  The role of complement in host resistance to bacteria.

Authors:  E J Brown; K A Joiner; M M Frank
Journal:  Springer Semin Immunopathol       Date:  1983

3.  Variable cross-reactivity of Pseudomonas aeruginosa lipopolysaccharide-code-specific monoclonal antibodies and its possible relationship with serotype.

Authors:  S Yokota; M Terashima; J Chiba; H Noguchi
Journal:  J Gen Microbiol       Date:  1992-02

4.  Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa.

Authors:  M J Rosok; M R Stebbins; K Connelly; M E Lostrom; A W Siadak
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

5.  Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies.

Authors:  M Finke; G Muth; T Reichhelm; M Thoma; M Duchêne; K D Hungerer; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

6.  Structure of an extracellular cross-reactive polysaccharide from Pseudomonas aeruginosa immunotype 4.

Authors:  N A Kocharova; Y A Knirel; A S Shashkov; N K Kochetkov; G B Pier
Journal:  J Biol Chem       Date:  1988-08-15       Impact factor: 5.157

7.  Monoclonal antibodies as probes to examine serotype-specific and cross-reactive epitopes of lipopolysaccharides from serotypes O2, O5, and O16 of Pseudomonas aeruginosa.

Authors:  J S Lam; M Y Handelsman; T R Chivers; L A MacDonald
Journal:  J Bacteriol       Date:  1992-04       Impact factor: 3.490

8.  Cloning and surface expression of Pseudomonas aeruginosa O antigen in Escherichia coli.

Authors:  J B Goldberg; K Hatano; G S Meluleni; G B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

9.  Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins.

Authors:  G B Pier; M Grout; D Desjardins
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

10.  Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model.

Authors:  H E Gilleland; L B Gilleland; M R Fowler
Journal:  J Med Microbiol       Date:  1993-02       Impact factor: 3.196

View more
  11 in total

1.  Virulence properties of Pseudomonas aeruginosa lacking the extreme-stress sigma factor AlgU (sigmaE).

Authors:  H Yu; J C Boucher; N S Hibler; V Deretic
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.

Authors:  Akinobu Kamei; Yamara S Coutinho-Sledge; Joanna B Goldberg; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2010-12-13       Impact factor: 3.441

Review 3.  Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa.

Authors:  H L Rocchetta; L L Burrows; J S Lam
Journal:  Microbiol Mol Biol Rev       Date:  1999-09       Impact factor: 11.056

4.  Microbial pathogenesis in cystic fibrosis: pulmonary clearance of mucoid Pseudomonas aeruginosa and inflammation in a mouse model of repeated respiratory challenge.

Authors:  H Yu; M Hanes; C E Chrisp; J C Boucher; V Deretic
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

Review 5.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

6.  Lipopolysaccharide O-antigen chain length regulation in Pseudomonas aeruginosa serogroup O11 strain PA103.

Authors:  Erica Kintz; Jennifer M Scarff; Antonio DiGiandomenico; Joanna B Goldberg
Journal:  J Bacteriol       Date:  2007-12-07       Impact factor: 3.490

Review 7.  Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.

Authors:  Gerald B Pier
Journal:  Int J Med Microbiol       Date:  2007-04-27       Impact factor: 3.473

8.  Two distinct loci affecting conversion to mucoidy in Pseudomonas aeruginosa in cystic fibrosis encode homologs of the serine protease HtrA.

Authors:  J C Boucher; J Martinez-Salazar; M J Schurr; M H Mudd; H Yu; V Deretic
Journal:  J Bacteriol       Date:  1996-01       Impact factor: 3.490

9.  The O-specific polysaccharide lyase from the phage LKA1 tailspike reduces Pseudomonas virulence.

Authors:  Tomasz Olszak; Mikhail M Shneider; Agnieszka Latka; Barbara Maciejewska; Christopher Browning; Lada V Sycheva; Anneleen Cornelissen; Katarzyna Danis-Wlodarczyk; Sofya N Senchenkova; Alexander S Shashkov; Grzegorz Gula; Michal Arabski; Slawomir Wasik; Konstantin A Miroshnikov; Rob Lavigne; Petr G Leiman; Yuriy A Knirel; Zuzanna Drulis-Kawa
Journal:  Sci Rep       Date:  2017-11-24       Impact factor: 4.379

10.  Complement Effectors of Inflammation in Cystic Fibrosis Lung Fluid Correlate with Clinical Measures of Disease.

Authors:  Laura A Sass; Pamela S Hair; Amy M Perkins; Tushar A Shah; Neel K Krishna; Kenji M Cunnion
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.